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cians were asked if they considered that the patient had CGD
and also objective criteria (serum creatinine  2 mg/dl or
MDRD  50 ml/min), were applied. RESULTS: A total of 872
patients were analyzed 62% male, mean (SD) age 54 (13) years.
Ethiology of end stage renal failure: 32.7% chronic glomerulo-
nephritis, 19.8% unknown, 12.4% polycystic disease, 7.6%
chronic pielonephritis, 8% diabetes, 5.9% hypertension, 15.7%
other. Mean (SD) transplant evolution 8.2 (5.1) years. Mean
donor age 42 years. CGD was diagnosed in 35% of the patients
according to the investigators’ criteria and in 55.5% according to
objective criteria. In 40% of the patients that were diagnosed of
CGD by objective criteria the clinician had not considered this
diagnosis. Graft biopsy was performed in 31% of patients with
investigators’ criteria of CGD. The presence of proteinuria con-
ducted to a biopsy more than a rise in serum creatinine. Time
from transplant to biopsy was greater in patients with antipro-
teinuric treatment (p = 0,032). Immunosuppressive treatment
changes were not associated to biopsy histological data. The
creatinine slope showed a direct relationship with the total
number of treated acute rejections (Pearson’s r: 0,12; p < 0.001).
CONCLUSIONS: This study shows an existing difference
between the clinician’s perception of CGD and its objective pres-
ence. Nephrologists are more sensitive to glomerular disease than
to renal impairment itself. Changes in the immunosuppressive
treatment due to presence of CGD are performed late and with
poor results.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Greece has grown nearly 13% since
2003. Approximately 83% of prevalent ESRD patients are on
dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are
available, hemodialysis (HD) and peritoneal dialysis (PD). Both
have been shown to have similar outcomes yet most (91%)
dialysis patients in Greece receive HD. The objective of this
evaluation is to project a ﬁve-year impact on total direct dialy-
sis costs if utilization of the less expensive equally, effective PD
were increased to 15% of all dialysis. METHODS: An Excel-
based budget impact model was used to estimate the impact of
a shift in modality utilization. The model takes into account
dialysis modality shares, annual average cost of treating
patients per modality, annual ESRD growth rate, patient years
at risk and years to reach new dialysis modality distribution.
Cost data from a recent Greek study were used. At baseline
(2007) there were 8189 patients undergoing dialysis therapy,
91% using HD and 9% using PD. Annual direct cost per
patient were €36,247 for in-center HD and €30,719 for PD. We
applied a 2% annual ESRD growth rate; set the target PD
modality share at 15%, and that this target would be achieved
in the ﬁfth year. Total costs included equipment/infrastructure,
diagnostic services, drugs and consumables, staff salaries, and
operational costs/overheads. RESULTS: If PD utilization gradu-
ally increases to 15% by 2012, the cumulative 5-year cost
would be reduced by €6.5 million. Alternatively, the savings
could provide an additional 258 patient-years of dialysis treat-
ment. CONCLUSIONS: In Greece, an increased use of PD can
reduce the direct costs of dialysis treatment which then
provides an opportunity to use scarce health care resources on
other pressing needs.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Turkey has grown nearly 36% from
2001 to 2005. Approximately 90% of prevalent ESRD patients
are on dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are avail-
able, hemodialysis (HD) and peritoneal dialysis (PD). Both have
been shown to have similar outcomes yet most (87%) dialysis
patients in Turkey receive HD. The objective of this evaluation
is to project a ﬁve-year impact on total direct dialysis costs if
utilization of the less expensive equally effective PD were
increased to 20% of all dialysis. METHODS: An Excel-based
budget impact model was used to estimate the impact of a shift
in modality utilization. The model takes into account dialysis
modality shares, annual average cost of treating patients per
modality, annual ESRD growth rate, patient years at risk and
years to reach new dialysis modality distribution. Cost data from
a recent Turkish study were used. At baseline (2005) there were
39,161 patients undergoing dialysis therapy, 13% using PD.
Annual costs per patient were US$23,342 for in-center HD and
US$17,779 for PD. We applied a 6% annual ESRD growth rate;
set the target PD modality share at 20%, and that this target
would be achieved in the ﬁfth year. Total costs included the costs
of dialysis related supplies (e.g., dialysis solutions) and the cost of
drugs (e.g., erythropoietin). RESULTS: If PD utilization gradu-
ally increases to 20% by 2010, the cumulative 5-year cost would
be reduced by $38.8 million. Alternatively, the savings could
provide an additional 2420 patient-years of dialysis treatment.
CONCLUSIONS: In Turkey, an increased use of PD can reduce
the dialysis and drug-related costs of dialysis treatment which
then provides an opportunity to use scarce health care resources
on other pressing needs.
PUK4
PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN
THETREATMENT OF OVERACTIVE BLADDER SYNDROME
IN ITALY
Pradelli L, Iannazzo S
AdRes Srl,Turin, Italy
OBJECTIVES: To investigate the pharmacoeconomic perfor-
mance of the treatment with solifenacin, a bladder-selective
muscarinic receptor antagonist, as compared to tolterodine and
placebo, in Italian patients with overactive bladder (OAB).
METHODS: A simple Markov model simulates 52-weeks clini-
cal and economical outcomes associated with the treatment with
solifenacin (5 mg/die), tolterodine ER (4 mg/die), and no treat-
ment, in a cohort representative of the Italian OAB population,
relying on RCT efﬁcacy and national cost data, and using 1-week
cycles. Only direct health care costs were considered. The main
analysis is conducted from the point of view of the patient, as
drugs for OAB are not currently reimbursed in Italy, whereas
incontinence medical devices are only to few selected patients. A
complementary scenario was elaborated to explore the conse-
quences of a hypothetical reimbursement decision by the Italian
NHS at half of the current retail price and only to incontinent
and responding OAB patients. RESULTS: Both active treatments
produce signiﬁcant improvements in symptoms and quality of
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